The DiaChemo Principle

We propose to develop a point-of-care device for quantification of chemotherapeutic drugs in small body fluid samples by highly selective nanoparticle extraction and liquid crystal detection incorporated in a microfluidic lab-on-a chip device (optofluidics based)allowing the real-time drug monitoring. This will improve the therapeutic outcome and reduced health care costs.

Expected impact and future development

  • easy adaption of selective nanoparticles by ligand exchange to other drug molecules
  • liquid crystal matrix follows nanoparticle or/and drug-metabolite hydrophobicity
  • availability of easy and fast TDM will create the need for better drug monitoring